Berkshire Hathaway Announces First Takeover Since Warren Buffett's Exit
Berkshire Hathaway announced a cash acquisition of homebuilder Taylor Morrison Home for $8.5 billion, paying $72.50 per share—a 24% premium to the market price. The deal marks the conglomerate’s first takeover since Warren Buffett stepped down as CEO at the end of 2025. Berkshire’s cash hoard has swelled to a record $397 billion, prompting the firm to finally put its liquidity to work. Berkshire shares slipped 2.5% while Taylor Morrison’s stock edged up after the announcement.
How S&P 500 Giant Pfizer Is Tackling Hard-To-Treat Cancers
Pfizer announced that its Braftovi‑based regimen more than doubled progression‑free survival for patients with BRAF‑mutated colon cancer, extending median PFS to 15.2 months versus 8.3 months with chemotherapy. The combination also cut overall death risk by 44% and lowered progression...
Stock Market Week Ahead: Chipmaker Aims For 9th Straight Triple-Digit Gain
The S&P 500 logged its ninth straight weekly gain, adding to 26 new closing highs this year, while the Nasdaq recorded its eighth gain in nine weeks. AI‑chip leader Credo Technology is targeting a ninth consecutive quarter of triple‑digit earnings growth,...
TTMI Stock Shows How Swing Trading Rules Lead To Success
TTM Technologies (TTMI) surged nearly 40% after breaking its 50‑day moving average in early April, then found support around $150 following an earnings‑driven gap up. The trade was entered with a half‑position and a tightened stop‑loss at $154.72, capping potential...
Eli Lilly Breaks Out Amid Vaccine Push; Three More Stocks At Highs
Eli Lilly’s stock surged past its entry point, reaching an all‑time high of $1,149.10 after reporting a 156 % jump in first‑quarter earnings to $8.55 per share and a 56 % revenue increase to $20 billion, far exceeding analysts' forecasts. The pharma giant is...
Anthropic Leapfrogs OpenAI In Valuation. But Here's One Thing To Know.
Anthropic’s latest funding round raised $65 billion, pushing its pre‑IPO valuation to roughly $965 billion—surpassing OpenAI’s $852 billion estimate. The AI startup projects $10.9 billion in Q2 revenue, more than double its Q1 earnings, and expects operating profitability ahead of OpenAI. A key distinction...
S&P 500, Nasdaq Set More Record Highs On Iran Deal Hopes; Tesla, First Solar In Or Near Buy Zones
U.S. equities surged Thursday as the S&P 500 and Nasdaq posted new record highs, driven by optimism after reports that U.S. and Iranian negotiators reached a cease‑fire extension. The diplomatic breakthrough eased geopolitical risk premiums, lifting broad market sentiment. Analysts also...
SentinelOne Plunges As Cybersecurity Firm's Q1 Revenue, Guidance Disappoint
SentinelOne reported first‑quarter earnings of $0.04 per share, topping the 2‑cent consensus, while revenue of $277 million met expectations and grew 21% year‑over‑year. Annualized recurring revenue from subscription products rose 23% to $1.163 billion, slightly above analyst forecasts. However, the company’s July‑quarter...
This Bullish Options Trade On Apple Stock Could Pay Off With Limited Risk
Apple shares have rallied about 26% since a May low, pushing the stock near all‑time highs. To capture further upside while limiting downside, the article recommends a bull call spread using a 315‑strike long call and a 325‑strike short call...
Chip Leader Flashes Buy Signal After Earnings Sell-Off
Nova (NVMI) saw its shares rally nearly 50% year‑to‑date as AI‑driven demand for chip‑process measurement tools surged. After a brief sell‑off following its Q1 earnings release, the stock is now trading near a 5% buy zone above the 507.27 entry...
IBD Stock Of The Day: Data Center Builder Sterling Infrastructure At New Entry
Sterling Infrastructure (STRL) surged about 6% as its stock rebounded from a technical support level, extending a year‑to‑date gain of roughly 155%. The builder of AI data‑center facilities posted Q1 revenue up 92% YoY to $825.7 million and earnings of $3.09...
Dow Jones Leader Amazon, AI Stock Quanta, Monster Beverage In Or Near Buy Zones
Amazon is hovering in a 5% buy zone above the 258.60 point, buoyed by Jefferies’ $320 price target that highlights accelerating AWS AI revenue. Travere Therapeutics broke out of its buy range after the FDA approved its drug Filspari for...
Here's How We Avoided Spinning In Circles On Sphere Stock
Sphere Entertainment delivered a standout Q1, rallying nearly 30% from its lows and staying above its 50‑day moving average. The firm’s swing‑trading desk entered the stock twice, first adding to a half position before a quick pullback forced an exit,...
Analyst Upgrades AI Data Center Play On Potential Deals. Stock Crosses Buy Point.
Generac (GNRC) received a Jefferies upgrade to buy, with the price target lifted to $302 from $239, suggesting a 13% upside. The upgrade hinges on the company’s expanding data‑center generator business, where its Baudouin engines are gaining traction among hyperscalers....
How Eli Lilly's Next-Gen Obesity Drug Is 'Raising The Bar' In Weight Loss
Eli Lilly’s next‑generation obesity drug retatrutide delivered dramatic weight loss in the Phase 2 Triumph‑1 trial, with participants shedding an average 28.3% of body weight (about 70 lb) after 80 weeks and up to 30.3% (≈85 lb) in a 104‑week extension. Nearly half of...